## Background: 6-thioguanine nucleotides (6-tgn) are active metabolites of azathioprine (aza) and 6-mercaptopurine (6mp). higher remission rates have been observed in patients with higher 6-tgn levels. however, many physicians prescribe aza/6mp using milligrams per kilogram (mg/kg) dosing regimens
Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger
โ Scribed by Andrew B. Grossman; Angela J. Noble; Petar Mamula; Robert N. Baldassano
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 83 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
โฆ Synopsis
Background:
6-mercaptopurine (6-mp) and its prodrug azathioprine (aza) are effective for the induction and maintenance of remission and reduction of corticosteroid exposure for pediatric inflammatory bowel disease (ibd). the standard dose of 6-mp is 1.0-1.5 mg/kg/day and for aza is 2.0-2.5 mg/kg/day. the aim of this study was to determine whether ibd patients 6 years of age and younger require higher than standard doses of 6-mp/aza to achieve clinical remission.
Methods:
Clinical data was collected retrospectively for all ibd patients 6 years of age or younger treated with 6-mp/aza at the children's hospital of philadelphia.
Results:
Thirty patients met the inclusion criteria. ibd was diagnosed at a median age of 3.3 years (25-75th %ile 2.3-4.6 years) and 6-mp/aza was initiated at a median age of 3.9 years (range 0.8-6.8 years). after dose escalation, the median aza-equivalent dose was 3.1 mg/kg/day (25-75th %ile 2.5-3.5, max. dose 5.1 mg/kg/day). at the final recorded dose, 8/13 (62%) patients receiving aza >3.0 mg/kg/day achieved clinical remission, compared to 2/12 (17%) receiving 2-3 mg/kg/day (p = 0.02). the risk of having active disease was on average 85% lower if the aza-equivalent dose was >3.0 mg/kg/day (95% confidence interval [ci] 72%-93%). adverse events were experienced by 4/30 patients (hepatitis, n = 2; leukopenia, n = 2). no patients had to discontinue 6-mp/aza, and all laboratory abnormalities improved spontaneously or with dose reduction.
Conclusions:
The standard dose of 6-mp/aza may not be adequate for ibd patients 6 years of age and younger. closely monitored dose escalation beyond the standard dosing range is effective and well-tolerated.
๐ SIMILAR VOLUMES